^
Association details:
| Biomarker: | IDH2 mutation |
|---|---|
| Cancer: | Glioma |
| Drug: | P-500 (PRMT5 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM).
Published date:
05/25/2023
Excerpt:
Among the 16 IDH1/2-mutated (IDH+) pts with glioma, we observed 2 complete responses (CR; 1 ongoing, duration: 111+ weeks; 1 discontinued, duration: 33 weeks), 1 unconfirmed partial response (PR), and 8 pts with stable disease (SD)….PRT811 demonstrated an acceptable safety profile and clinical activity in pts with glioma and MUM.
DOI:
10.1200/JCO.2023.41.16_suppl.3008
Trial ID:
